title: Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography.
abstract: The effect of acute, intravenous administration of physostigmine on measures of brain activity and cognitive functioning were investigated in 14 patients with Alzheimer's disease. Regional cerebral glucose metabolism was assessed using (18F)-fluoro-2-deoxy-D-glucose and positron emission tomography, and cerebral blood flow was assessed using 123I-iodoamphetamine single photon emission tomography. Although physostigmine enhanced cerebral blood flow in most patients, only one patient showed significant clinical improvement. This patient, however, also showed a very pronounced improvement in cerebral glucose metabolism. It is concluded that these preliminary findings hold considerable promise for our appreciation of the pathophysiology of dementing illness as well as our understanding of centrally acting compounds of interest in Alzheimer's disease.
authors.affiliation: Dementia Research Clinic, School of Medicine, Johns Hopkins University, Baltimore, MD 21205.
authors.forename: L
authors.initials: L
authors.lastname: Tune
authors.forename: J
authors.initials: J
authors.lastname: Brandt
authors.forename: J J
authors.initials: JJ
authors.lastname: Frost
authors.forename: G
authors.initials: G
authors.lastname: Harris
authors.forename: H
authors.initials: H
authors.lastname: Mayberg
authors.forename: C
authors.initials: C
authors.lastname: Steele
authors.forename: A
authors.initials: A
authors.lastname: Burns
authors.forename: J
authors.initials: J
authors.lastname: Sapp
authors.forename: M F
authors.initials: MF
authors.lastname: Folstein
authors.forename: H N
authors.initials: HN
authors.lastname: Wagner
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000523:psychology; D000662:Amphetamines; D001786:Blood Glucose / Q000378:metabolism*; D001921:Brain / Q000098:blood supply / Q000000981:diagnostic imaging / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D003847:Deoxyglucose / Q000031:analogs & derivatives / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010830:Physostigmine / Q000627:therapeutic use*; D010865:Pilot Projects; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D000662:Amphetamines; D001786:Blood Glucose; D019788:Fluorodeoxyglucose F18; C041336:4-iodoamphetamine; D003847:Deoxyglucose; D010830:Physostigmine